This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sauter, E. R. Articles by Ridge, J. A. Search for Related Content PubMed PubMed Citation Articles by Sauter, E. R. Articles by Ridge, J. A.

Prolonged Response to Antisense Cyclin D1 in a Human Squamous Cancer Xenograft Model¹

Department of Surgery, Thomas Jefferson University [E. R. S.], Division of Population Science [S. C. L., S. L.], and the Department of Surgery [J. A. R.], Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111, and the Department of Molecular and Cellular Biology, The Wistar Institute, Philadelphia, Pennsylvania 19104 [E. R. S., M. H.]

Local recurrence of squamous cell cancer (SCC) causes high morbidity and is often readily accessible, making such patients potential candidates for gene therapy. Cyclin D1 (CD1), critical in the G₁-S transition in the cell cycle, is amplified in 20–50% and overexpressed in up to 80% of head and neck SCC. Our earlier studies indicated that CD1 expression increased with progression from low grade to high grade dysplasia, and that treatment of established tumors with antisense cyclin D1 (AS-cyclin D1) led to tumor regression during a one week evaluation period. We hypothesized that: 1) CD1 expression increases with disease progression to advanced SCC, and 2) AS-cyclin D1 therapy would lead to prolonged tumor regression in a xenograft model of human SCC. CD1 expression, evaluated by immunostain in 30 stage III/IV head and neck SCC, increased in the basal layer from normal-dysplasia (P = 0.06) and from dysplasia-carcinoma (P = 0.004). In the germinative layer CD1 expression increased from dysplasia-carcinoma (P = 0.002) but not from normal-dysplasia. Western blotting of eight SCC and two transformed keratinocyte cell lines demonstrated CD1 overexpression in 8/10 (80%) lines. An 11th cell line (A431) had previously been shown to overexpress cyclin D1. 8/9 (89%) cell lines overexpressing CD1 formed tumors in immunodeficient mice, whereas 0/2 cell lines without CD1 overexpression formed a tumor. Three established SCCs, one fast growing, one with moderate growth rate (with CD1 overexpression) and one slow growing (without increased CD1), shrank significantly for 2–4 weeks after AS-cyclin D1 treatment, while tumors transduced with control vector grew. Cyclin D1 expression increases in frequency with disease progression, and antisense cyclin D1 was effective in a xenograft model of human cancer, independent of tumor growth rate.

This article has been cited by other articles:

				X. TIAN, A. CHAKRABARTI, N. V. AMIRKHANOV, M. R. ARUVA, K. ZHANG, B. MATHEW, C. CARDI, W. QIN, E. R. SAUTER, M. L. THAKUR, et al. External Imaging of CCND1, MYC, and KRAS Oncogene mRNAs with Tumor-Targeted Radionuclide-PNA-Peptide Chimeras Ann. N.Y. Acad. Sci., November 1, 2005; 1059(1): 106 - 144. [Abstract] [Full Text] [PDF]

				L. H. Kalish, R. A. Kwong, I. E. Cole, R. M. Gallagher, R. L. Sutherland, and E. A. Musgrove Deregulated Cyclin D1 Expression Is Associated with Decreased Efficacy of the Selective Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Gefitinib in Head and Neck Squamous Cell Carcinoma Cell Lines Clin. Cancer Res., November 15, 2004; 10(22): 7764 - 7774. [Abstract] [Full Text] [PDF]

				R CHRISTOPHER, A DHIMAN, J FOX, R GENDELMAN, T HABERITCHER, D KAGLE, G SPIZZ, I G. KHALIL, and C HILL Data-Driven Computer Simulation of Human Cancer Cell Ann. N.Y. Acad. Sci., May 1, 2004; 1020(1): 132 - 153. [Abstract] [Full Text] [PDF]

				X. TIAN, M. R. ARUVA, P. S. RAO, W. QIN, P. READ, E. R. SAUTER, M. L. THAKUR, and E. WICKSTROM Imaging Oncogene Expression Ann. N.Y. Acad. Sci., December 1, 2003; 1002(1): 165 - 188. [Abstract] [Full Text] [PDF]

				E. R. Sauter, U.-C. Yeo, A. von Stemm, W. Zhu, S. Litwin, D. S. Tichansky, G. Pistritto, M. Nesbit, D. Pinkel, M. Herlyn, et al. Cyclin D1 Is a Candidate Oncogene in Cutaneous Melanoma Cancer Res., June 1, 2002; 62(11): 3200 - 3206. [Abstract] [Full Text] [PDF]

				M. E. Laurance, D. B. Starr, E. F. Michelotti, E. Cheung, C. Gonzalez, A. W. Tam, J. Deikman, C. A. Edwards, and A. J. Bardwell Specific down-regulation of an engineered human cyclin D1 promoter by a novel DNA-binding ligand in intact cells Nucleic Acids Res., February 1, 2001; 29(3): 652 - 661. [Abstract] [Full Text] [PDF]